These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34806021)

  • 21. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
    Reinhart K; Wiegand-Löhnert C; Grimminger F; Kaul M; Withington S; Treacher D; Eckart J; Willatts S; Bouza C; Krausch D; Stockenhuber F; Eiselstein J; Daum L; Kempeni J
    Crit Care Med; 1996 May; 24(5):733-42. PubMed ID: 8706447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
    Geven C; Blet A; Kox M; Hartmann O; Scigalla P; Zimmermann J; Marx G; Laterre PF; Mebazaa A; Pickkers P
    BMJ Open; 2019 Feb; 9(2):e024475. PubMed ID: 30782906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial.
    Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B
    Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
    Hu XY; Zhang W; Wang D; Sun Y; Hu Z; Zang B; Feng Y; Wang H; Zhou J; Zhao Q; Liu H; Wang T; Jiang W; Wang CY; Jin C; Dong K; Chen S; Yao X; Hu P; Du B;
    J Crit Care; 2023 Aug; 76():154294. PubMed ID: 37116228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis: The HYPRESS Randomized Clinical Trial.
    Keh D; Trips E; Marx G; Wirtz SP; Abduljawwad E; Bercker S; Bogatsch H; Briegel J; Engel C; Gerlach H; Goldmann A; Kuhn SO; Hüter L; Meier-Hellmann A; Nierhaus A; Kluge S; Lehmke J; Loeffler M; Oppert M; Resener K; Schädler D; Schuerholz T; Simon P; Weiler N; Weyland A; Reinhart K; Brunkhorst FM;
    JAMA; 2016 Nov; 316(17):1775-1785. PubMed ID: 27695824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjunctive use of physostigmine salicylate (Anticholium®) in perioperative sepsis and septic shock: study protocol for a randomized, double-blind, placebo-controlled, monocentric trial (Anticholium® per Se).
    Zimmermann JB; Pinder N; Bruckner T; Lehmann M; Motsch J; Brenner T; Hoppe-Tichy T; Swoboda S; Weigand MA; Hofer S
    Trials; 2017 Nov; 18(1):530. PubMed ID: 29126416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD14 receptor occupancy in severe sepsis: results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14).
    Reinhart K; Glück T; Ligtenberg J; Tschaikowsky K; Bruining A; Bakker J; Opal S; Moldawer LL; Axtelle T; Turner T; Souza S; Pribble J
    Crit Care Med; 2004 May; 32(5):1100-8. PubMed ID: 15190957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
    Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
    J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity of treatment effect of vilobelimab in COVID-19: a secondary analysis of a randomised controlled trial.
    van Amstel RBE; Slim MA; Lim EHT; Rückinger S; Seymour CW; Burnett BP; Bos LDJ; van Vught LA; Riedemann NC; van de Beek D; Vlaar APJ;
    Crit Care; 2024 Jun; 28(1):210. PubMed ID: 38943192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
    Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
    Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group.
    Dhainaut JF; Vincent JL; Richard C; Lejeune P; Martin C; Fierobe L; Stephens S; Ney UM; Sopwith M
    Crit Care Med; 1995 Sep; 23(9):1461-9. PubMed ID: 7664546
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of the nitric oxide synthase inhibitor NG-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002).
    Bakker J; Grover R; McLuckie A; Holzapfel L; Andersson J; Lodato R; Watson D; Grossman S; Donaldson J; Takala J;
    Crit Care Med; 2004 Jan; 32(1):1-12. PubMed ID: 14707554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
    Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC
    Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Vitamin C, Thiamine, and Hydrocortisone on Ventilator- and Vasopressor-Free Days in Patients With Sepsis: The VICTAS Randomized Clinical Trial.
    Sevransky JE; Rothman RE; Hager DN; Bernard GR; Brown SM; Buchman TG; Busse LW; Coopersmith CM; DeWilde C; Ely EW; Eyzaguirre LM; Fowler AA; Gaieski DF; Gong MN; Hall A; Hinson JS; Hooper MH; Kelen GD; Khan A; Levine MA; Lewis RJ; Lindsell CJ; Marlin JS; McGlothlin A; Moore BL; Nugent KL; Nwosu S; Polito CC; Rice TW; Ricketts EP; Rudolph CC; Sanfilippo F; Viele K; Martin GS; Wright DW;
    JAMA; 2021 Feb; 325(8):742-750. PubMed ID: 33620405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.
    Fisher CJ; Slotman GJ; Opal SM; Pribble JP; Bone RC; Emmanuel G; Ng D; Bloedow DC; Catalano MA;
    Crit Care Med; 1994 Jan; 22(1):12-21. PubMed ID: 8124953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Sodium Selenite Administration and Procalcitonin-Guided Therapy on Mortality in Patients With Severe Sepsis or Septic Shock: A Randomized Clinical Trial.
    Bloos F; Trips E; Nierhaus A; Briegel J; Heyland DK; Jaschinski U; Moerer O; Weyland A; Marx G; Gründling M; Kluge S; Kaufmann I; Ott K; Quintel M; Jelschen F; Meybohm P; Rademacher S; Meier-Hellmann A; Utzolino S; Kaisers UX; Putensen C; Elke G; Ragaller M; Gerlach H; Ludewig K; Kiehntopf M; Bogatsch H; Engel C; Brunkhorst FM; Loeffler M; Reinhart K;
    JAMA Intern Med; 2016 Sep; 176(9):1266-76. PubMed ID: 27428731
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.